Clinical Effectiveness and Safety of Intraoperative Methadone in Patients Undergoing Laparoscopic Hysterectomy

Sponsor
University of Aarhus (Other)
Overall Status
Recruiting
CT.gov ID
NCT03908060
Collaborator
(none)
126
1
2
41.9
3

Study Details

Study Description

Brief Summary

The role of a single-dose of intraoperative methadone on postoperative pain and opioid consumption in patients undergoing hysterectomy remains scarcely explored. A prospective double-blind, randomised controlled trial investigating the effect of a single-dose of intraoperative methadone in patients scheduled for same day hysterectomy is therefore conducted.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Background with aim: Hysterectomy is the most common major gynaecological procedure in the world and hysterectomy on benign indications are increasingly being performed as same-day surgery. Therefore, perioperative anaesthesia has moved towards the use of very short-acting opioids with the incitement to speed up extubation and facilitate hospital discharge. However, the potential consequence is that more patients experience pain and discomfort.

Methadone has several desirable pharmacological features, and a single intraoperative dose of the long acting opioid could therefore theoretically expand the analgesic window and reduce postoperative opioid consumption compared to the more conventional use of short-acting opioids. The aim of this study is to investigate the effect of a single-dose of intravenous intraoperative methadone on postoperative opioid consumption, pain and side effects in patients scheduled for hysterectomy for benign indications. Our primary hypothesis is that intravenous perioperative methadone reduces opioid consumption (oral cumulative equivalent dose) by 30% during the first 24 postoperative hours compared to intravenous morphine.

Methods: 126 patients will be included in an investigator-initiated, prospective, randomised, double-blind, controlled trial with two arms: an intervention arm (methadone 0.2 mg/kg ideal body weight) and a control arm (morphine 0.2 mg/kg ideal body weight). The study will be GCP-monitored, and is approved by the Danish Health and Medicines Authority (2018-004351-20) and the Central Denmark Region Committees on Health Research Ethics (1-10-72-365-18).

Hypothesis: The results will probably be applicable to other types of surgery involving visceral pain, and thus the present study has the potential to improve the pain management for a large number of patients undergoing surgery.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
126 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized controlled trialRandomized controlled trial
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Randomisation and study medication will be handled by the hospital pharmacy. All research team members, caregiving clinicians and enrolled patients will be blinded to the study allocation arms and the randomisation list will be concealed until all statistical analyses are made.
Primary Purpose:
Treatment
Official Title:
Clinical Effectiveness and Safety of Intraoperative Methadone in Patients Undergoing Laparoscopic Hysterectomy: a Prospective, Double-blind, Randomised Controlled Trial
Actual Study Start Date :
May 6, 2019
Anticipated Primary Completion Date :
Jul 31, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intravenous single-dose methadone

A 10 ml syringe with 2 mg/ml of methadone will be prepared and and study drug will be administered as intravenous bolus dose (0.2 mg/kg) corresponding to 1 ml for every 10 kg of ideal body weight (height (cm) - 105).

Drug: Methadone
One intravenous administration of methadone (0.2 mg/kg ideal body weight)

Active Comparator: Intravenous single-dose morphine

A 10 ml syringe with 2 mg/ml of morphine will be prepared and study drug will be administered as intravenous bolus dose (0.2 mg/kg) corresponding to 1 ml for every 10 kg of ideal body weight (height (cm) - 105).

Drug: Morphine
One intravenous administration of morphine (0.2 mg/kg ideal body weight)

Outcome Measures

Primary Outcome Measures

  1. Opioid consumption at 24 hours after extubation (cumulative opioid consumption) [24 hours]

    cumulative opioid consumption in oral morphine equivalents

  2. Opioid consumption at 6 hours after extubation (cumulative opioid consumption) [6 hours]

    cumulative opioid consumption in oral morphine equivalents

Secondary Outcome Measures

  1. Pain intensity (NRS, 0-10) at rest and coughing [0-48 hours after extubation]

    Numeric Rating Scale (NRS) ranging from 0 (no pain) to 10 (worst imaginable pain)

  2. Postoperative side effects/ adverse events (nausea and vomiting, sedation, hypoventilation, and hypoxemia) [0-72 hours after extubation]

    Number of patients

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 110 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients scheduled for elective laparoscopic hysterectomy for benign indications
Exclusion Criteria:
  • American Society of Anaesthesiologists (ASA) physical status IV or V

  • prolonged QT-interval assessed by electrocardiogram (> 440 milliseconds)

  • Existing treatment with medications prolonging the QT-interval

  • Hysterectomy due to malignancy or acute bleeding disorders

  • Allergy to study drugs

  • Preoperative daily use of opioids

  • Severe respiratory insufficiency

  • Heart failure

  • Acute alcohol intoxication/delirium tremens

  • Increased intracranial pressure

  • Acute liver disease

  • Acute abdominal pain

  • Liver insufficiency

  • Kidney insufficiency

  • Treatment with rifampicin

  • Breastfeeding

  • Inability to provide informed consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Anaesthesiology and Intensive Care, Horsens Regional Hospital Horsens Central Denmark Region Denmark 8700

Sponsors and Collaborators

  • University of Aarhus

Investigators

  • Principal Investigator: Kristian Friesgaard, MD, PhD, Department of Anaesthesiology and Intensive Care, Horsens Regional Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University of Aarhus
ClinicalTrials.gov Identifier:
NCT03908060
Other Study ID Numbers:
  • 01052019
First Posted:
Apr 9, 2019
Last Update Posted:
Sep 29, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 29, 2021